Xiaflex
(Collagenase clostridium histolyticum)Phase 3Small molecule
Xiaflex is used to break down and dissolve excess collagen buildup in conditions like Dupuytren's contracture (a hand deformity where fingers curl inward) and Peyronie's disease (curved penis caused by scar tissue). The enzyme works by digesting the problematic scar tissue to improve function and appearance.[1] Xiaflex is currently being investigated across 17 indications[3], with its most advanced program in Phase 3.[1]
Xiaflex is one of 181 small molecule programs targeting Plantar Fasciitis. It is currently in Phase 3.
17
Indications
26
Total Trials
5
Active Trials
180
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 17 indications
Competition
Competitive Landscape
210 competitors in Diabetic Foot
#DrugCompanyPhaseTrials
1Xiaflex
GGrupo Espanol de Tumores Neuroendocrinos
Phase 3
Isordil
AstraZenecaPhase 3
Zyvox
PfizerPhase 3
Cysteine Hydrochloride
NovartisPhase 3
Invanz
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Cubicin
BBaxter Healthcare Corporation
Phase 3
Urokinase
Mmedac GmbH
Phase 3
Bemiparin
RRovi Pharmaceuticals Laboratories
Phase 3
Biochaperone Combo
AAdocia
Phase 3
Beta-Glucan
BBiotec Pharmacon ASA
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Treatment5 trials
Dupuytren's Disease4 trials
Contracture4 trials
Effectiveness3 trials
Peyronie's Disease2 trials
Delayed Dose Collagenase Clostridium Histolyticum (CCH) Protocol for Men With Peyronie's Disease
Recruiting·CCharitable Union for the Research and Education of Peyronie's Disease·Phase 4·NCT06649539·40 enrolled
8 more indications
Erectile Dysfunction1 trial
Double-blind1 trial
Adhesive Capsulitis of the Shoulder1 trial
Safety and Efficacy1 trial
Plantar Fasciitis1 trial
Surgery1 trial
Investigation of Surgery, Collagenase, and Restorex for the Improvement of Peyronie's
Active, not recruiting·CCharitable Union for the Research and Education of Peyronie's Disease·Phase 4·NCT04786106·40 enrolled
Regulatory
FDA Approval Timeline[4]
Feb 2, 2010
XIAFLEX
BLA BLA125338
Sources
References
- [1]
- [2]
- [3]
- [4]
- [5]
Details